Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 4018

Drug Profile

REGN 4018

Alternative Names: Anti MUC16-CD3 antibody; REGN4018

Latest Information Update: 10 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Mucin inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 07 Jan 2019 Regeneron and Sanofi amend immuno-oncology collaboration agreement to narrow down its scope and agree to co-develop REGN 4018 for Cancer
  • 21 May 2018 Phase-I/II clinical trials in Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03564340)
  • 21 May 2018 Phase-I/II clinical trials in Fallopian tube cancer (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT03564340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top